FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154066874> ?p ?o ?g. }

• W2154066874 endingPage "516" @default.
• W2154066874 startingPage "507" @default.
• W2154066874 abstract "Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma. Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy. The primary end point was the overall response rate. Secondary end points were duration of response, progression-free survival, overall survival, and safety.The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clinical prognostic factors. Patients had received a median of three prior therapies. The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea. Grade 3 or higher hematologic events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%). A response rate of 68% (75 patients) was observed, with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate. With an estimated median follow-up of 15.3 months, the estimated median response duration was 17.5 months (95% confidence interval [CI], 15.8 to not reached), the estimated median progression-free survival was 13.9 months (95% CI, 7.0 to not reached), and the median overall survival was not reached. The estimated rate of overall survival was 58% at 18 months.Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01236391.)" @default.
• W2154066874 created "2016-06-24" @default.
• W2154066874 creator A5000991854 @default.
• W2154066874 creator A5002011167 @default.
• W2154066874 creator A5003766253 @default.
• W2154066874 creator A5006499454 @default.
• W2154066874 creator A5007119947 @default.
• W2154066874 creator A5008964504 @default.
• W2154066874 creator A5011398209 @default.
• W2154066874 creator A5014007447 @default.
• W2154066874 creator A5015774745 @default.
• W2154066874 creator A5017100241 @default.
• W2154066874 creator A5019866348 @default.
• W2154066874 creator A5032960925 @default.
• W2154066874 creator A5034128046 @default.
• W2154066874 creator A5036657478 @default.
• W2154066874 creator A5036965407 @default.
• W2154066874 creator A5040141808 @default.
• W2154066874 creator A5046049357 @default.
• W2154066874 creator A5046659441 @default.
• W2154066874 creator A5048416913 @default.
• W2154066874 creator A5055441745 @default.
• W2154066874 creator A5056946123 @default.
• W2154066874 creator A5059022907 @default.
• W2154066874 creator A5060314041 @default.
• W2154066874 creator A5062625211 @default.
• W2154066874 creator A5066599847 @default.
• W2154066874 creator A5068953821 @default.
• W2154066874 creator A5069054551 @default.
• W2154066874 creator A5075889094 @default.
• W2154066874 creator A5086953858 @default.
• W2154066874 creator A5089736242 @default.
• W2154066874 creator A5089882481 @default.
• W2154066874 date "2013-08-08" @default.
• W2154066874 modified "2023-10-15" @default.
• W2154066874 title "Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma" @default.
• W2154066874 cites W1580240122 @default.
• W2154066874 cites W1910349555 @default.
• W2154066874 cites W1933973263 @default.
• W2154066874 cites W1979816280 @default.
• W2154066874 cites W1996708966 @default.
• W2154066874 cites W2002438998 @default.
• W2154066874 cites W2003110967 @default.
• W2154066874 cites W2009937603 @default.
• W2154066874 cites W2029409133 @default.
• W2154066874 cites W2032482627 @default.
• W2154066874 cites W2065338378 @default.
• W2154066874 cites W2071549499 @default.
• W2154066874 cites W2075875145 @default.
• W2154066874 cites W2093055119 @default.
• W2154066874 cites W2110474703 @default.
• W2154066874 cites W2115343219 @default.
• W2154066874 cites W2117964879 @default.
• W2154066874 cites W2122048891 @default.
• W2154066874 cites W2133201432 @default.
• W2154066874 cites W2142489003 @default.
• W2154066874 cites W2146029333 @default.
• W2154066874 cites W2147422161 @default.
• W2154066874 cites W2171771895 @default.
• W2154066874 cites W2329375415 @default.
• W2154066874 cites W2608724752 @default.
• W2154066874 cites W3041047318 @default.
• W2154066874 doi "https://doi.org/10.1056/nejmoa1306220" @default.
• W2154066874 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4513941" @default.
• W2154066874 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23782157" @default.
• W2154066874 hasPublicationYear "2013" @default.
• W2154066874 type Work @default.
• W2154066874 sameAs 2154066874 @default.
• W2154066874 citedByCount "1355" @default.
• W2154066874 countsByYear W21540668742012 @default.
• W2154066874 countsByYear W21540668742013 @default.
• W2154066874 countsByYear W21540668742014 @default.
• W2154066874 countsByYear W21540668742015 @default.
• W2154066874 countsByYear W21540668742016 @default.
• W2154066874 countsByYear W21540668742017 @default.
• W2154066874 countsByYear W21540668742018 @default.
• W2154066874 countsByYear W21540668742019 @default.
• W2154066874 countsByYear W21540668742020 @default.
• W2154066874 countsByYear W21540668742021 @default.
• W2154066874 countsByYear W21540668742022 @default.
• W2154066874 countsByYear W21540668742023 @default.
• W2154066874 crossrefType "journal-article" @default.
• W2154066874 hasAuthorship W2154066874A5000991854 @default.
• W2154066874 hasAuthorship W2154066874A5002011167 @default.
• W2154066874 hasAuthorship W2154066874A5003766253 @default.
• W2154066874 hasAuthorship W2154066874A5006499454 @default.
• W2154066874 hasAuthorship W2154066874A5007119947 @default.
• W2154066874 hasAuthorship W2154066874A5008964504 @default.
• W2154066874 hasAuthorship W2154066874A5011398209 @default.
• W2154066874 hasAuthorship W2154066874A5014007447 @default.
• W2154066874 hasAuthorship W2154066874A5015774745 @default.
• W2154066874 hasAuthorship W2154066874A5017100241 @default.
• W2154066874 hasAuthorship W2154066874A5019866348 @default.
• W2154066874 hasAuthorship W2154066874A5032960925 @default.
• W2154066874 hasAuthorship W2154066874A5034128046 @default.
• W2154066874 hasAuthorship W2154066874A5036657478 @default.
• W2154066874 hasAuthorship W2154066874A5036965407 @default.
• W2154066874 hasAuthorship W2154066874A5040141808 @default.

• next